NEXGEL (NXGL) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for June 17, 2025, at corporate headquarters in Langhorne, PA, with proxy materials distributed primarily via Internet to reduce costs and environmental impact.
Shareholders are encouraged to vote via Internet, phone, or mail, with detailed instructions provided for both record and street name holders.
Board recommends voting FOR all director nominees, FOR the incentive plan amendment, FOR executive compensation, FOR a three-year say-on-pay frequency, and FOR auditor ratification.
Voting matters and shareholder proposals
Election of five directors to serve until the 2026 Annual Meeting.
Approval of the Fourth Amendment to the 2019 Long-Term Incentive Plan, increasing authorized shares by 780,000 to 1,651,429.
Advisory vote on executive compensation (say-on-pay) and on the frequency of future say-on-pay votes, with Board recommending every three years.
Ratification of Turner, Stone & Company, L.L.P. as independent auditor for 2025.
Other business as may properly arise at the meeting.
Board of directors and corporate governance
Board consists of five male directors, all with significant business, finance, or medical experience; no females or underrepresented minorities.
Four directors are independent per NASDAQ rules; Board committees include Audit, Compensation, and Nominating & Corporate Governance.
Board and committees met regularly in 2024, with full attendance by all directors.
Code of Business Conduct and Ethics and insider trading policy in place; clawback policy adopted for incentive compensation.
Latest events from NEXGEL
- Hydrogel innovation and strategic partnerships fuel rapid growth and expanding product lines.NXGL
Planet MicroCap Showcase: VEGAS 20253 Feb 2026 - Record Q2 revenue and strong outlook driven by branded products and Silly George growth.NXGL
Q2 20242 Feb 2026 - Q3 revenue up 141% to $2.94M, gross margin 43.6%, but losses and risks persist.NXGL
Q3 202414 Jan 2026 - Strong growth from product innovation, acquisitions, and major partnerships, with profitability in focus.NXGL
IAccess Alpha–Buyside Best Ideas Winter Virtual Conference 202411 Jan 2026 - Record revenue growth and improved margins set stage for positive EBITDA in 2025.NXGL
Q4 202424 Dec 2025 - Vote to increase authorized common stock to 1B shares for future flexibility is recommended.NXGL
Proxy Filing2 Dec 2025 - Q1 2025 revenue up 121%, margin at 42.4%, and positive EBITDA targeted for 2025.NXGL
Q1 202527 Nov 2025 - Q2 2025 revenue doubled and margins improved, but going concern risks persist.NXGL
Q2 202523 Nov 2025 - Q3 revenue steady at $2.93M, gross margin up, nine-month revenue up 52.7%, risks persist.NXGL
Q3 202517 Nov 2025